<DOC>
	<DOCNO>NCT03026972</DOCNO>
	<brief_summary>There three population Recombinant Mycobacterium tuberculosis Vaccine Freeze-dried ( AEC/BC02 ) phase I clinical research . The clinical study adopt randomize open research design . Population I 25 subject receive Tuberculin purify protein derivative ( TB-PPD ) skin test specific gamma-interferon ( γ-IFN ) detection whose result negative ; Population II 75 subject receive Tuberculin purify protein derivative ( TB-PPD ) ESAT6-CFP10 skin test different arm , specific gamma-interferon ( γ-IFN ) detection whose result negative.75 subject whose three kind detection result positive ( specific gamma interferon detection ( γ-IFN ) , TB-PPD ESAT6-CFP10 ) name population III . Three population screen time . After filtrate , inject population I start firstly.After ensure safety population I population II population III carry implementation time .</brief_summary>
	<brief_title>A Phase ⅠStudy Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried</brief_title>
	<detailed_description>Firstly , participant placebo group complete first needle intramuscular injection . Secondly , low-dose adjuvant group inject sure security placebo group two hour . Thirdly , accord safe result low-dose adjuvant group 3 day , low-dose vaccine group inject . The population II/ III randomly divide placebo group , low-dose adjuvant group , middle- dose adjuvant group , high-dose adjuvant group , low-dose vaccine group , middle-dose vaccine group high-dose vaccine group , group 10 participant , except placebo group 15 case . Each participant immune one type placebo , adjuvant vaccination every two week , totally six stitch . In research , subject receive one dose drug subject experiment dose escalation . All subject population I randomly divide placebo ( 5 case ) ，low-dose adjuvant ( 10 case ) low-dose vaccine ( 10 case ) . The population Ⅰ subject receive 6 needle time placebo adjuvant vaccine haunch deep intramuscular injection provide security basis population Ⅱ population Ⅲ . The subject accept physical examination clinical research . Vital sign ( breathe , heart rate , blood pressure , body temperature ) volunteer needle injection 30min , 3day , 14day injection ; local reaction volunteer 30min , 3day , 14day injection ; subject accept alcohol detection needle injection ; routine blood , routine urine , liver kidney function , ECG injection 3 day first needle injection 14days sixth needle injection ; chest X-ray detection first injection 30 day sixth needle injection . All subject assess change immunological index first injection , 3 day first injection , fourth time injection 30 day sixth needle injection . The specific injection order follow : - All subject placebo group ( 5 case ) low-dose adjuvant group ( 10 case ) inject day , adjuvant group subject inject placebo group complete observe two hour safety ; - All subject low-dose vaccine ( 10 case ) injected third day placebo group adjuvant group subject observe safety . - The clinical study population Ⅱ population Ⅲ carry 3 day later low-dose vaccine group subject population Ⅰ observe safety ; Each subject inoculate dose drug every two week , total six agent . In conclusion , result Phase I Clinical Study population I evaluate safety different dose Recombinant Mycobacterium tuberculosis Vaccine Freeze-dried ( AEC/BCO2 ) different population , also provide safe basis Phase I Clinical Study population Ⅱ population Ⅲ . The populationⅠsubjects inject first needle injection observe safety 3 day conduct clinical research population Ⅱ Ⅲ Phase I Clinical . The study population Ⅱ/Ⅲ inject placebo adjuvant vaccination collect adverse event serious adverse event evaluate safety period clinical research . The 75 subject study population Ⅱand 75 subject population III meet inclusion criterion accord standard exclusion randomly divide placebo group , low-dose adjuvant group , middle-dose adjuvant group , high-dose adjuvant group , low-dose vaccine group , middle-dose vaccine group high-dose vaccine group , group 10 participant , except placebo group 15 cases.The subject accept physical examination clinical research , item physical examination population I . Specific injection order follow : - All subject populationⅡof low-dose placebo group adjuvant group inject sixth day , adjuvant group subject inject placebo group receive complete placebo observe two hour safety ; - The subject populationⅡof middle dose placebo group adjuvant group low dose vaccine group inject 3 day safety ninth day , time , low dose placebo group adjuvant group populationⅢwill inject . - The subject populationⅡof high dose placebo group adjuvant group middle dose vaccine group inject 4 day safety thirteen day , time , middle dose placebo group adjuvant group low dose vaccine group populationⅢwill inject . - The subject populationⅡof high dose vaccine group inject 3 day safety the16 day , time , high dose placebo group adjuvant group middle dose vaccine group populationⅢwill inject . ⑤ The subject populationⅢ high dose vaccine group inject 4 day safety 20 day . All subject vaccinate every two week , total six time vaccination .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged form 1840 year old . Body mass index range 1826 . Body Mass Index BMI : weight ( Kg ) / height ( M2 ) ; Physical condition : ECG , blood pressure , heart rate , respiratory status lab test indexed include blood , urine , liver kidney function normal minor abnormality abnormal symptom sign ; People normal examination Xray chest radiograph ; Agreed participate test sign inform consent ; Subjects comply requirement clinical trial protocol follow ; Subjects history tuberculosis ; Subjects acute chronic disease , acute infectious disease , dermatosis skin allergy cause various reason ; Subject participate clinical drug trial inoculate prophylactic immune globulin nearly 3 month ; Temperature normal . ( Temperature le equal 37℃ quiet state ) Suffering serious disease , e.g . cancer treatment , autoimmune disease , progressive atherosclerosis , diabetes accompanied complication , chronic obstructive pulmonary disease ( COPD ) need oxygen therapy , acute progressive liver kidney disease , congestive heart failure , etc ; Subjects important primary disease ; Subjects immune dysfunction abnormal , e.g . patient receive immunosuppressive agent immunosuppressive agent , receive immunoglobulin preparation outsider gastrointestinal blood product within 3 month , extract plasma infected immunodeficiency virus related disease ; Subjects take part clinical trial nearly 3 month ; Allergic constitution , e.g . patient allergic history two kind drug food , drug component . Substance abuse alcoholic ; Pregnant breast feed female ; Temperature 37℃ ; Mental physical disability ; Any case may influence test evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerance</keyword>
</DOC>